Compartilhar
Informação da revista
Vol. 93. Núm. 5.
Páginas 761-763 (1 setembro 2018)
Compartilhar
Compartilhar
Baixar PDF
Mais opções do artigo
Vol. 93. Núm. 5.
Páginas 761-763 (1 setembro 2018)
Open Access
Serum uric acid levels and hyperuricemia in patients with psoriasis: a hospital-based cross-sectional study*
Visitas
4266
Xin-Yu Gui1, Hong-Zhong Jin1, Zhen-Jie Wang2, Teng-Da Xu2
1 Department of Dermatology, Peking Union Medical College Hospital, Beijing, China.
2 Department of Physical Examination Center, Peking Union Medical College Hospital, Beijing, China.
Este item recebeu

Under a Creative Commons license
Informação do artigo
Resume
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Tabelas (2)
Table 1. Diagnostic criteria for metabolic syndrome recommended by the Chinese Diabetes Society (.3 of the following criteria are required)
Table 2. Predictors of hyperuricemia in the total sample of participants: multivariate logistic regression models
Mostrar maisMostrar menos
Abstract

A hospital-based cross-sectional study was performed, including 117 psoriatic patients and 117 controls matched for age, gender, and body mass index. Psoriatic patients had higher levels of serum uric acid (6.25 ± 1.62 vs 5.71 ± 1.35 mg/dl; P=0.019) and significantly greater prevalence of hyperuricemia (31.6% vs 16.2%; P=0.009) than individuals without psoriasis. Psoriatic patients had significantly higher serum uric acid than controls in subjects without metabolic syndrome. Multivariate logistic regression analysis showed that psoriasis can be a strong predictor of hyperuricemia (odds ratio 2.61; 95% confidence interval 1.34-5.00; P=0.004).

Keywords:
Body mass index
Metabolic syndrome X
Psoriasis
Uric acid
Texto Completo

Psoriasis is a chronic inflammatory and immune-mediated disease that affects the skin and involves several other organs and systems.1 Recent studies have linked psoriasis to metabolic syndrome.2,3 Similarly, it is generally accepted that hyperuricemia frequently accompanies psoriasis and psoriatic arthritis.4 The present study investigated the correlation between hyperuricemia and psoriasis by comparing serum uric acid (SUA) levels and prevalence of hyperuricemia in psoriatic patients and controls.

This descriptive, cross-sectional study included 117 adult psoriatic patients from the Department of Dermatology at Peking Union Medical College Hospital. Exclusion criteria were systemic antipsoriatic treatment within 3 months of enrolment and use of medications known to affect SUA level. Disease severity was scored using the Psoriasis Area and Severity Index (PASI). The control group consisted of 117 adult individuals selected in a 1:1 ratio matched for age, sex, and body mass index (BMI) with psoriatic patients from the Department of Physical Examination Centre.5 Metabolic syndrome was defined according to the criteria of the Chinese Diabetes Society (CDS) in 2004, which was more suitable for Chinese individuals (Table 1). 6 Hyperuricemia was defined as SUA level ≥7 mg/dl in men and ≥6 mg/dl in women, or allopurinol use. Statistical analysis was performed using SPSS 20 (IBM, Armonk, NY, USA) and GraphPad Prism software packages.

Table 1.

Diagnostic criteria for metabolic syndrome recommended by the Chinese Diabetes Society (.3 of the following criteria are required)

Components  Index 
Overweight or obesity  BMI ≥ 25.0 kg/m2 
Hyperglycemia  FBG ≥ 6.1 mmol/L and/or receiving treatment for diabetes mellitus 
High blood pressure  Blood pressure ≥ 140/90 mmHg and/or receiving treatment for hypertension 
Dyslipidemia  Fasting blood triglycerides ≥ 1.7 mmol/L and/or fasting blood HDL cholesterol < 0.9 mmol/L for men or < 1.0 mmol/L for women 

FBG: fasting blood glucose; HDL: high-density lipoprotein

Source: Advice, 2004.6

Patients with psoriasis had a higher prevalence of dyslipidemia (57.3% vs 39.3%, p=0.006), whereas high blood pressure, hyperglycemia, and metabolic syndrome did not differ significantly between the two groups. SUA levels were significantly higher in psoriatic patients compared to controls (6.25±1.62 vs 5.71±1.35mg/dl; p=0.019), and hyperuricemia was significantly more common in psoriatic patients than in control subjects (31.6% vs 16.2%; p=0.009). Male and female psoriatic patients had significantly higher SUA levels than their control counterparts (6.61±1.6 vs 6.06 ±1.2 mg/dl in men and 5.12±1.1 vs 4.58±1.0mg/dl in women). However, the results changed when participants were further stratified according to presence of metabolic syndrome. In subjects with metabolic syndrome, SUA levels were similar between psoriatic patients and controls (p=0.3537). Meanwhile, SUA levels were significantly higher in psoriatic patients than controls in subjects without metabolic syndrome (p=0.0035). Multivariate logistic regression showed that both psoriasis and metabolic syndrome, independently of each other, were risk factors for hyperuricemia (Table 2). Additionally, SUA level was positively correlated with BMI (r = 0.46; p <0.001), serum triglycerides (r = 0.30; p<0.001), and sex (r = 0.42; p<0.001) but was not significantly correlated with age or the duration of psoriasis. Among psoriatic patients, mean SUA was higher in patients with PASI ≥10 (n=112) than in those with PASI <10 (n=5) (SUA: 5.5±1.1 vs 6.3±1.6mg/dl). However, SUA was not significantly associated with PASI.

Table 2.

Predictors of hyperuricemia in the total sample of participants: multivariate logistic regression models

Clinical characteristics  Multivariate model 1  P value  Multivariate model 2  P value 
Age, y  0.986 (0.965-1.007)  0.179  0.981 (0.956-1.006)  0.140 
Sex, F vs M  0.520 (0.222-1.217)  0.132  0.810 (0.312-2.100)  0.665 
Psoriasis,  2.606 (1.359-4.996)  0.004  2.387 (1.136-5.014)  0.022 
Metabolic syndrome  2.997 (1.400-6.419)  0.005 
BMI, kg/m2  1.205 (1.087-1.336)  <0.001 
Hyperglycemia  0.726 (0.248-2.123)  0.559 
High blood pressure  1.857 (0.842-4.094)  0.125 
Dyslipidemia  3.582 (1.588-8.079)  0.002 

Model 1 = age, sex, presence of psoriasis, and metabolic syndrome;

Model 2 = age, sex, presence of psoriasis, BMI, hyperglycemia, high blood pressure, and dyslipidemia.

In this study, the prevalence of asymptomatic hyperuricemia was approximately twice as high in psoriatic patients than in matched controls. Moreover, psoriasis was a significantly positive predictor of hyperuricemia after adjusting for associated baseline characteristics such as age, sex, BMI, and other features of metabolic syndrome. To date, convincing evidence has indicated that psoriasis is independently associated with hyperuricemia.5,7-9 In line with the previous studies, our findings also demonstrated that psoriasis itself might contribute directly to hyperuricemia. However, our study did not find a correlation between serum uric acid levels and severity of psoriasis.

Our findings can have clinical implications, since elevated SUA independently predicts the development of cardiovascular disease events and mortality in nonpsoriatic populations.5 Some studies have suggested that psoriatic patients with hyperuricemia show remarkable improvement in their psoriasis when treated for hyperuricemia.7 Wei et al.10 concluded that higher doses of allopurinol contributed to lower risks of both cardiovascular events and mortality. We recommend that SUA should be routinely measured in patients with psoriasis, especially in those with obesity, hypertension, or dyslipidemia; drug treatment of hyperuricemia might be a useful strategy for psoriasis.

The limitation of our study was that the patients enrolled were biased toward having higher disease severity, since the study population was based in a tertiary medical center. Large interventional clinical trials are needed to confirm the association between hyperuricemia and psoriasis and the efficacy of high-dose allopurinol treatment in psoriatic patients with hyperuricemia.

Financial support: The present study was supported by the Medical and Health Science and Technology Innovation Project of the Chinese Academy of Medical Sciences (NO.2017-12M-3-020).

Conflict of interest: None.

References
[1.]
I. Grozdev, N. Korman, N. Tsankov.
Psoriasis as a systemic disease..
Clin Dermatol., 32 (2014), pp. 343-350
[2.]
A. Azfar, JM. Gomes.
Psoriasis and metabolic disease: epidemiology and pathophysiology..
Curr Opin Rheumatol., 20 (2008), pp. 416-422
[3.]
J. Machado-Pinto, S. Diniz Mdos, NC. Bavoso.
Psoriasis: new comorbidities..
An Bras Dermatol., 91 (2016), pp. 8-14
[4.]
A. Lambert, JM. Gomes.
Serum uric acid levels in psoriatic arthritis..
Ann Rheum Dis., 36 (1977), pp. 264-267
[5.]
P. Gisondi, G. Targher, A. Cagalli, G. Girolomoni.
Hyperuricemia in patients with chronic plaque psoriasis..
J Am Acad Dermatol., 70 (2014), pp. 127-130
[6.]
Advice on Metabolic Syndrome from Chinese Diabetes Society.
Chin J Diabetes., 12 (2004), pp. 156-161
[7.]
M. Goldman.
Uric acid in the etiology of psoriasis..
Am J Dermatopathol., 3 (1981 Winter), pp. 397-404
[8.]
Q. Zhang, C. Zhang, X. Song, H. Lin, D. Zhang, W. Meng.
A longitudinal cohort-based association study between uric acid level and metabolic syndrome in Chinese Han urban male population..
BMC Public Health., 12 (2012), pp. 419
[9.]
A. Lai, JM. Gomes.
Psoriasis and uric acid: a population-based cross-sectional study..
Clin Exp Dermatol., 41 (2016), pp. 260-266
[10.]
L. Wei, I.S. Mackenzie, Y. Chen, A.D. Struthers, TM. MacDonald.
Impact of allopurinol use on urate concentration and cardiovascular outcome..
Br J Clin Pharmacol., 71 (2011), pp. 600-607

Work conducted at the Peking Union Medical College Hospital, Beijing, China.

Copyright © 2018. Anais Brasileiros de Dermatologia
Baixar PDF
Idiomas
Anais Brasileiros de Dermatologia (Portuguese)
Opções de artigo
Ferramentas
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.